Loading…
Hosted by RBC Capital Markets · 🇺🇸 US · EN · 60 episodes
Established thought leaders with verified media credentials.
Perspectives from the cutting edge of biotech and pharma.The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.Lead today. Define tomorrow.
RBC Capital Markets hosts Pathfinders in Biopharma, a business show with 60 episodes published.
Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company’s amb
The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC’s Global Hea
This episode of RBC Pathfinders in Biopharma explores how next-generation retinal gene therapies could transform treatment for patients with wet AMD and diabetic macular edema. CCBO of 4D Molecular Therapeutics, Chris Si
Life sciences is a hub of dealmaking activity. Over the past year, more than 30 transactions valued at $1 billion or more have crossed the finish line. But the picture in other segments of healthcare is more mixed. At RB
Psychedelics are poised for a breakthrough in mainstream psychiatry, with high interest among physicians and patients alike. But does the infrastructure exist to deliver these treatments, given the clinical supervision r
Strong launches, positive sentiment, flowing capital, and favorable macro and policy indicators: the signals remain strong as the biotech sector enters 2026. Yet investors may need to search harder for opportunities this
Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and s
Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.
Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-sta
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Ca
Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidar
Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving lan
A surgeon in burns reconstruction, Matt Klein swapped the operating room for the equally high-pressure environment of drug development. In this episode of Pathfinders in Biopharma, he sets out the vision for the company
Scott Neidhold, Director in RBC’s Life Sciences Investment Banking Practice, sits down with Kristen Fortney, CEO and Co-Founder of BioAge, for a deep dive into how her company is turning cutting-edge aging science into r
Universal wisdom had it that a Republican sweep in the U.S. election would favor biotech. Appointments to the new administration’s healthcare leadership make that far less certain. What effect will this and other factors
Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Cra
Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains
The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Path
A very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business mode
Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutic
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Pathfinders in Biopharma, visit https://www.rbccm.com/en/gib/biopharma for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent business coverage.
Pathfinders in Biopharma is hosted by RBC Capital Markets. The show is categorised under business (investing) and has published 60 episodes.
Pathfinders in Biopharma has published 60 episodes.
Pathfinders in Biopharma regularly covers business, investing, news. It sits in the business category, with a investing focus.
Pathfinders in Biopharma is accessible for guests with genuine business expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Pathfinders in Biopharma hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Pathfinders in Biopharma average 17 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Pathfinders in Biopharma's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.